2026-04-13T01:19:31Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/96822025-10-24T10:24:08Zcom_2072_378070com_2072_378040col_2072_378092

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma Tamariz-Amador, Luis-Esteban Rodriguez-Otero, Paula Rosiñol, Laura Oriol, Albert Ríos-Tamayo, Rafael Gironella, Mercedes Jimenez-Ubieto, Ana Institut Català de la Salut [Tamariz-Amador LE, Rodríguez-Otero P] Clínica Universidad de Navarra, CCUN, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain. [Jiménez-Ubieto A] Hospital 12 de Octubre, Madrid, Spain. [Rosiñol L] Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain. [Oriol A] Institut Català d'Oncologia i Institut Josep Carreras, Badalona, Spain. [Ríos R] Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. [Gironella M] Vall d’Hebron Hospital Universitari, Barcelona, Spain Vall d'Hebron Barcelona Hospital Campus Mieloma múltiple - Tractament Mieloma múltiple - Prognosi Quimioteràpia combinada DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Plasma Cell::Multiple Myeloma Other subheadings::Other subheadings::Other subheadings::/drug therapy ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias de células plasmáticas::mieloma múltiple Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada Mieloma recién diagnosticado; Marcador pronóstico Newly diagnosed myeloma; Prognostic marker Mieloma recent diagnosticat; Marcador pronòstic Introduction Response kinetics is a well-established prognostic marker in acute lymphoblastic leukemia. The situation is not clear in multiple myeloma (MM) despite having a biomarker for response monitoring (monoclonal component [MC]). Materials and Methods We developed a mathematical model to assess the prognostic value of serum MC response kinetics during 6 induction cycles, in 373 NDMM transplanted patients treated in the GEM2012Menos65 clinical trial. The model calculated a “resistance” parameter that reflects the stagnation in the response after an initial descent. Results Two patient subgroups were defined based on low and high resistance, that respectively captured sensitive and refractory kinetics, with progression-free survival (PFS) at 5 years of 72% and 59% (HR 0.64, 95% CI 0.44-0.93; P = .02). Resistance significantly correlated with depth of response measured after consolidation (80.9% CR and 68.4% minimal residual disease negativity in patients with sensitive vs. 31% and 20% in those with refractory kinetics). Furthermore, it modulated the impact of reaching CR after consolidation; thus, within CR patients those with refractory kinetics had significantly shorter PFS than those with sensitive kinetics (median 54 months vs. NR; P = .02). Minimal residual disease negativity abrogated this effect. Our study also questions the benefit of rapid responders compared to late responders (5-year PFS 59.7% vs. 76.5%, respectively [P < .002]). Of note, 85% of patients considered as late responders were classified as having sensitive kinetics. Conclusion This semi-mechanistic modeling of M-component kinetics could be of great value to identify patients at risk of early treatment failure, who may benefit from early rescue intervention strategies. 2023-06-08T07:12:13Z 2023-06-08T07:12:13Z 2022-09 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Tamariz-Amador LE, Rodríguez-Otero P, Jiménez-Ubieto A, Rosiñol L, Oriol A, Ríos R, et al. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 Sep;22(9):e844-e852. 2152-2650 https://hdl.handle.net/11351/9682 10.1016/j.clml.2022.04.024 35688793 000864016000003 http://hdl.handle.net/11351/9682 eng Clinical Lymphoma Myeloma and Leukemia;22(9) https://doi.org/10.1016/j.clml.2022.04.024 Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ info:eu-repo/semantics/openAccess application/pdf Elsevier Scientia